Log In
BCIQ
Print this Print this
 

BMS-986168 (formerly IPN007)

  Manage Alerts
Collapse Summary General Information
Company Bristol-Myers Squibb Co.
DescriptionHumanized mAb targeting microtubule-associated protein tau (MAPT; tau; FTDP-17)
Molecular Target Microtubule-associated protein tau (tau) (MAPT) (FTDP-17)
Mechanism of ActionAntibody
Therapeutic ModalityBiologic: Antibody
Latest Stage of DevelopmentPreclinical
Standard IndicationAlzheimer's disease (AD)
Indication DetailsTreat Alzheimer's disease (AD)
Regulatory Designation
Partner

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

$725.0M

$175.0M

$550.0M


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone

05/05/2014

$725.0M

$175.0M

$550.0M

Get a free BioCentury trial today